Clearbridge BioMedics (CBB) specialises in novel platforms with applications in oncology research and diagnostics. It is a spin-off from the National University of Singapore (NUS) / SMART MIT and is the first incubatee of Clearbridge Accelerator, a high-technology incubator backed by the Singapore Government’s National Research Foundation (NRF).

The ClearCell® FX1 System by Clearbridge BioMedics provide a label-free means of Circulating Tumour Cell (CTC) enrichment that offers a myriad of possibilities for downstream analysis on the output CTCs. Utilising patented award winning microfluidic technologies, Clearbridge BioMedics aims to provide the next generation of non-invasive “liquid biopsy” approaches for cancer screening, diagnosis, staging, personalised medicine and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers across Asia, Europe and North America.

Events
AUG22-23TUE - WED
Precision Medicine & Big Data Congress: Asia [click me]

22-23 AUGUST 2017 | SEOUL, S.KOREA | PRESENTATION & BOOTH #3

Learn More
AUG15-18TUE - FRI
Next Generation Dx Summit 2017 [click me]

15-18 AUGUST 2017 | WASHINGTON DC, USA

Learn More
OCT4-7WED - SAT
ACTC 2017 [click me]

4-7 OCTOBER 2017 | RHODES, GREECE | BOOTH #10

Learn More
Contact Us for more information